^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:HER2 Positive Breast Cancer
    Drug:Perjeta (pertuzumab) (HER2 dimerization inhibitor) +
    Hercessi (trastuzumab-strf) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Efficacy and cardiac safety in the neoadjuvant treatment of stage II-III HER2- positive breast cancer with Docetaxel, Carboplatin, Pertuzumab and HLX02: a single-arm study

    Excerpt:
    ...Patients with stage II – III HER2 positive breast cancer, t > 2cm; (Note: follow the 2018 asco-cap HER2 positive criteria); 2. ...
    Trial ID:
    ChiCTR2100041951
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SABCS 2023
    Title:

    Real-world first line use of trastuzumab biosimilar (HLX02), pertuzumab and chemotherapy for Chinese patients with HER2-positive metastatic breast cancer

    Published date:
    12/02/2023
    Excerpt:
    The trastuzumab biosimilar HLX02 demonstrated comparable efficacy and safety to Herceptin when combined with pertuzumab and chemotherapy for Chinese patients with HER2-positive advanced breast cancer in real world first-line treatment, which suggested that HLX02 may provide another option of Her2-targeted therapy combined with pertuzumab for Chinese patients.
    Secondary therapy:
    Chemotherapy